Skip to main content

ImmunityBio, Inc.

IBRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001326110

In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 406 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.

Holders of 5% or more of IBRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of ImmunityBio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of IBRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Cambridge Equities, LP13D/A64.80%745.5M shares−1.50 ppfrom 66.30%Mar 12, 20218 filingsAug 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

8 Schedule 13D and 13G filings on ImmunityBio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on IBRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 6, 20266:50 PM ETCambridge Equities, LPand 5 others13D/A64.80%745.5M shares−1.50 ppfrom 66.30%Jul 31, 2026SEC
Feb 25, 20269:51 PM ETCambridge Equities, LPand 5 others13D/A66.30%745.6M shares−2.60 ppfrom 68.90%Feb 23, 2026SEC
Nov 10, 20257:43 PM ETCambridge Equities, LPand 6 others13D/A68.90%744.0M shares–Nov 10, 2025SEC
Jan 4, 2024Cambridge Equities, LP13D/AOld format–––SEC
Sep 21, 2023Cambridge Equities, LP13D/AOld format–––SEC
May 23, 2023Cambridge Equities, LP13D/AOld format–––SEC
Dec 7, 2022Cambridge Equities, LP13D/AOld format–––SEC
Mar 12, 2021Cambridge Equities, LP13D/AOld format–––SEC

Form 144: proposed insider sales

11 notices from officers, directors and other affiliates planning to sell ImmunityBio, Inc. shares, newest first.

Form 144 notices for IBRX
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Oct 5, 202610:21 AM ETSimon Barry J.Officer · Director560.0K$7.66MOct 5, 202610b5-1THE CHARLES SCHWAB CORPORATIONSEC
Oct 2, 20264:26 PM ETCheryl CohenDirector81.1K$752.2KOct 2, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jul 2, 20264:31 PM ETCheryl L CohenOfficer131.2K$1.21MJul 2, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jul 1, 20264:29 PM ETChristobel SeleckyDirector159.5K$1.40MJul 1, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jun 30, 20264:35 PM ETChristobel SeleckyDirector1.00K$8.77KJun 30, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jun 29, 20264:44 PM ETChristobel SeleckyDirector95.7K$833.7KJun 29, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jun 4, 202611:02 AM ETSimon Barry J.Officer · Director268.0K$2.95MJun 4, 202610b5-1THE CHARLES SCHWAB CORPORATIONSEC
Feb 23, 20264:28 PM ETChristobel SeleckyDirector25.0K$217.5KFeb 23, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jan 20, 20264:29 PM ETChristobel SeleckyDirector25.0K$138.0KJan 20, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Jan 20, 202611:05 AM ETSimon Barry J.Officer · Director572.0K$5.91MJan 20, 202610b5-1THE CHARLES SCHWAB CORPORATIONSEC
Jan 16, 20264:22 PM ETChristobel SeleckyDirector50.0K$197.5KJan 16, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC